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A B S T R A C T
Schizophrenia is a clinical syndrome of variable, but profoundly disruptive, psychopathology that involves cognition,
emotion, perception and other aspects of behavior. The Remission in Schizophrenia Working Group (RSWG) has defined
criteria for symptomatic remission based on achieving and maintaining a consistently low symptom threshold for at
least six consecutive months. Aim of our study was to determine which antipsychotic are used in the treatment of patients
with schizophrenia, as well as to assess are there differences between patients treated with typical and atypical anti-
psychotics and how many of them are in remission according to the defined remission criteria. All outtreated patients
with schizophrenia treated at the University Department of Psychiatry, University Hospital Osijek in the period of three
months were assessed. The patients were divided in two groups, one group of patients treated with typical antipsychotics,
and the other group treated with atipycal antipsychotics. All of them were assessed with specially designed questionnaire
about sociodemographic data, than with 8 item of PANSS (remission criteria), and with Clinical Global Impression
scale. The authors analysed 193 patients with schizophrenia, 65 (33.7%) of them were treated with typical antipsychotics,
and 128 (66.3%) patients were treated with atypical antipsychotics. Younger and work active patients are more often
treated with atypical antipsychotics. Authors did not found statistically significant differences in two groups of patients
regarding the scores on PANSS, CGI and number of patients in remission.
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Introduction
Schizophrenia is a clinical syndrome of variable, but
profoundly disruptive, psychopathology that involves co-
gnition, emotion, perception and other aspects of behav-
ior. The expression of these manifestations varies across
patients over time, but the effect of the illness is always
severe and is usually long lasting. Clinicans should ap-
preciate that the diagnosis of schizophrenia is based en-
tirely on the psychiatric history and mental status exam-
ination. There is no laboratory test for schizophrenia1.
Schizophrenia is one of the most severe and disabling
psychiatric disorders. Antipsychotic drugs offer consider-
able benefits in controlling symptoms and preventing
relapse2.
The Remission in Schizophrenia Working Group
(RSWG) has defined criteria for symptomatic remission
based on achieving and maintaining a consistently low
symptom threshold for at least six consecutive months3.
Aim of our study was to determine which antipsy-
chotic are used in the treatment of patients with schizo-
phrenia, as well as to assess are there differences be-
tween patients treated with typical and atypical anti-
psychotics and how many of them are in remission ac-
cording to the defined remission criteria.
Methodology and Results
All outtreated patients with schizophrenia treated at
the University Department of Psychiatry, University Hos-
pital Osijek in the period of three months were assessed.
The patients were divided in two groups, one group of pa-
tients treated with typical antipsychotics, and the other
group treated with atipycal antipsychotics. We consid-
ered flufenazine, haloperidole as typical antipsychotics
and risperidone, olanzapine, quetiapine and ziprasidone
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as atypical antipsychotics. All of them were assessed with
specially designed questionnaire about sociodemographic
data, than with 8 item of PANSS (remission criteria), and
with Clinical Global Impression scale. Rehabilitation ef-
forts were the same for all patients.
The authors analysed 193 patients with schizophre-
nia, 65 (33.7%) of them were treated with typical anti-
psychotics, and 128 (66.3%) patients were treated with
atypical antipsychotics. In the group of patients treated
with typical antipsychotics 30 of the patients were trea-
ted with flufenazine in the doses from 5–15 mg per day,
and 35 of the patients were treated with haloperidole in
doses from 4–12 mg per day. While in the group of the pa-
tients treated with atypical antipsychotics 49 of the pa-
tients were treated with risperidone in doses from 4–8
mg per day, 47 of the patients were treated with olan-
zapine in doses from 10–20 mg per day, 30 of the patients
were treated with quetiapine in doses 600–900 mg per
day and 2 of the patients were treated with ziprazidone
in dose of 80 mg per day.
The authors found statistically significant differences
between patients sex as well as in the mean age of the pa-
tients treated with typical and atypical antipsychotics.
(Table 1) Also in the level of working activity persisted
statictically significant difference, as we can see more pa-
tients treated with atypical antipsychotics were still wor-
king.
Our results also suggest that there is statisticaly sig-
nificant difference in the duration of psychiatric treat-
ment between those two groups of patients as well as sta-
tistically significant difference in the number of visits to
the psychiatrist in the last two years. (Table 2.) There
was no statistically significant difference between tne
number of hospitalisations, and in duration of hospital-
ization, and in the number of prescribed medications.
(Table 2).
Only item from the PANSS remision criteria in which
we observed statistically significant difference between
two groups of patients was G 9 (Unusal thought content)
(Table 3).
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TABLE 1
SOCIODEMOGRAPHIC DATA ABOUT TWO GROUPS OF PATIENTS
Number of patients treated with
typical antipsychotics



























REMARKS ABOUT USED TREATMENTS IN TWO GROUPS OF PATIENTS
Remarks about used treatments
patients treated with
typical antipsychotics
patients treated with atyp-
ical antipsychotics
Statistical significance




























Number of prescribed psychopharmacs D=2 D= 2–3 U= 3874
p>0.05
(Mann-Whitney)
Authors didn’t find statistically significant difference
between the group of patients treated with typical and
the group of patients treated with atypical antipsychotics
in the CGI score, neither in the overall PANSS remission
criteria score. (Table 4.)
In our group of patients 98 of them (50.8%) were in
remission according to the PANSS
remission criteria. Thirty five (53.8%) of patients
treated with typical antipsychotics were in remission and
63 (49.2%) of patients treated with atypical antipsycho-
tics were in remission.
We can conclude that 2/3 of schizophrenic patients
were treated with atypical antipsychotics. Younger and
work active patients are more often treated with atypical
antipsychotics. Authors did not found statistically signif-
icant differences in two groups of patients regarding the
scores on PANSS, CGI and number of patients in remis-
sion.
Discussion
Standard measurment of symptoms and function in
schizophrenia patients is crucial for research and prac-
tice. Numerous instruments have been developed; how-
ever, their use has been limited to the research context4,5.
Limitations to their use in clinical practice include: time
constraints, difficulties for standardized administration,
as well as for their analysis and interpretation4.
A recent review proposed the use of very short ver-
sions of well-established instruments for assessing symp-
tomatic remission in clinical pratice, emphasizing both
attenuation and disappeearance of symptoms and stabil-
ity in that clinical situation3. This proposal might help
overcome most of the difficulties in using standardized
symptoms instruments in the evaluation of schizophre-
nia patients in routine clinical care4.
Formal assessment of remission in schizophrenia is a
crucial outcome both for clinical research and for prac-
tice. Such measurement is carried out only in research
settings owing to the burden in administration, and diffi-
culties scoring and interpreting the results4.
The Remission in Schizophrenia Working Group
(RSWG) has defined criteria for symptomatic remission
based on achieving and maintaining a consistently low
symptom threshold for at least six consecutive months3.
From results of study done by Gasquet et al. remis-
sion can be achieved in a high proportion of patients. Fac-
tors such as being previously untreated, having paid
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TABLE 3




















D=2 (minimal) D=3 (low)
U=3664 p>0.05
(Mann-Whitney)
N4 (Passive/apathetic social withdrawal)
D=2 (minimal) D=3 (low)
U=3570 p>0.05
(Mann-Whitney)
N6 (Lack of spontaneity and flow of conversation)
D= 1–2 D=3 (low)
U=3772 p>0.05
(Mann-Whitney)
G5 (Mannerism / posturing)
D=2 (minimal) D=2 (minimal)
U=3969 p>0.05
(Mann-Whitney)
G9 (Unusal thought content)




RESULTS ON THE CGI SCALE AND PANSS REMISSION CRITERIA
Patients on typical antipsycotics Patients on atypical antipsychotics Statistical significance
CGI D=3 D=3 U=3348 p>0.05
(Mann-Whitney)
PANSS remission criteria D=1 D=2 U=3742 p>0.05
(Mann-Whitney)
employement and taking olanzapine are predictors of
remission6.
We can see in our group of patients 98 of them
(50.8%) were in remission according to the PANSS re-
mission criteria. 35 (53.8%) of patients treated with typ-
ical antipsychotics were in remission and 63 (49.2%) of
patients treated with atypical antipsychotics were in re-
mission.
Acutely ill schizophrenia patients treated with ari-
piprazole demonstrated a significantly higher rate of
symptomatic remission acros 52 weeks compared with
haloperidol-treated patients. The similar remission rates
among trial completers in both treatment groups, com-
bined with fewer AE-related discontinuations and lower
EPS medication use in the aripiprazole group, suggest
that better tolerability with aripiprazole may have con-
tributed to superior overall remission rates7.
Comparing the patients treated with typical and atyp-
ical antipsychotics in our study we didn’t observe any
statistically significant difference in remission rates be-
tween patients treated with typical and atypical anti-
psychotics. We did not observe statistically significant
differences in two groups of patients regarding the scores
on PANSS, CGI and number of patients in remission.
Recently, the 'Remission in Schizophrenia Working
Group' proposed remission criteria consisting of a re-
duction to mild levels on key symptoms for at least 6
months.
The study done by Emsley et al. applied these remis-
sion criteria to a large first-episede psychosis sample in
order to 1.determine the rates of remission, 2.explore
predictors of remission, and 3. test the external validity
of these criteria8.
The results suggest that the remission criteria, al-
though based solely on core symptom improvement, can
effectively identify patients who have a more favorable
overall outcome8. Several studies presented that emis-
sion from the first episode occurs in about 6 months and
in about 3 months for later episodes. Hypomania and sim-
ple depression predict early remission from the first epi-
sode; flat affect and grandiose delusions predict longer
episodes and shorter remissions later in the course9,10.
Further clarification of factors predicting the out-
come in schizophrenia is needed.
There is good evidence that poor insight predicts poor
outcome, although perhaps not simply as a consequence
of poor compliance. Further support is provided for a link
between duration of untreated psychosis and long-term
outcome. The relationship between cognition and out-
come is complex, with specific cognitive deficits appar-
ently predicting particular outcome domains. Early trea-
tment response is closely related to long-term outcome.
Outcome studies may be flawed by sample selection bias,
and a lack of standardized outcome measures.
Several predictors are potentially modifiable, indicat-
ing that they should be targets for therapeutic interven-
tion. More carefully designet studies are needed. Re-
cently proposed criteria for remission are helpful, and
should facilitate cross-sample comparisons8.
According to Mortimer symptom rating scales are
now established in schizophrenia research but their scores
are not the same as outcome. Symptom rating scale
scores can only comprise a limited part of outcome mea-
surement. Standardised remission criteria may present
advantages in outcome research11.
Although schizophrenia refers mainly to an intrinsic
biological vulnerability, only maintenence studies with
follow-up of 2 years at most are available. Relapses ap-
pear unpredictable and occur even after long-term suc-
cessful remission during antipsychotic treatment.
Since rehabilitation efforts have effects only after
long-term endeavours, antipsychotic relapse prevention
should be maintained for long periods. It is reasonable to
treat patients suffering from schizophrenia and related
psychoses for longer periods than indicated by the cur-
rent guidelines12.
Conclusion
Until the definition for 'recovery' is further eluci-
dated, factors such as symptom control and remission,
and functional aspects of recovery such as improvements
in cognition and social functioning, which are quantifi-
able, should be used as measures of treatment outcome
and markers of recovery13.
Recent work has focused on schizophrenia as a 'defi-
cit' state but little attention has been paid to defining ill-
ness plasticity in terms of symptomatic remission.
The introduction of standardized remission criteria
may offer significant opportunities for clinical practice,
health services research and clinical trials14,15.
We can conclude that in our sample of patients 2/3 of
schizophrenic patients were treated with atypical anti-
psychotics. Younger and work active patients are more
often treated with atypical antipsychotics. Authors did
not found statistically significant differences in two groups
of patients regarding the scores on PANSS remission cri-
teria, CGI and number of patients in remission.
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PSIHOFARMAKOTERAPIJA I REMISIJA BOLESNIKA SA SHIZOFRENIJOM
S A @ E T A K
Schizofrenija je bolest koja poga|a sve sfere li~nosti, kogniciju, emocije, percepciju i druge aspekte pona{anja. The
Remission in Schizophrenia Working Group (RSWG) je definirala kriterije za simptomatsku remisiju zasnovano na
postignutom i zadr`anom niskom stupnju simptoma u trajanju barem {est mjeseci. Cilj na{e studije je bio odrediti koji
su antipsihotici kori{teni u lije~enju schizofrenije, te da li postoje razlike izme|u bolesnika lije~enih tipi~nim i atipi~nim
antipsihoticima kao i utvrditi koliko ih je u remisiji u prema zadanim smjernicama kriterija remisije. Svi ambulantno
lije~eni shizofreni bolesnici na Psihijatrijskoj klinici, KB Osijek u periodu od tri mjeseca su analizirani. Bolesnici su
podijeljeni u dvije skupine, jednu skupinu bolesnika lije~enih sa tipi~nim antipsihoticima i drugu skupinu bolesnika
lije~enih sa atipi~nim antipsihoticima. Svi su procijenjeni sa upitnikom o sociodemografskim podacima, zatim sa 8
itema PANSS-a (kriteriji za remisiju) i sa CGI ljestvicom. Autori su analizirali 193 bolesnika sa shizofrenijom od kojih
je 65 (33,7%) lije~eno sa tipi~nim antipsihoticima, a 128 (6,3%) sa atipi~nim antipsihoticima. Mla|i i radno aktivni
bolesnici su lije~eni sa atipi~nim antipsihoticima. Autori nisu prona{li statisti~ki zna~ajnu razliku izme|u dvije grupe
bolesnika na PANSS skoru, na CGI skoru niti u usporedbi bolesnika koji su uremisiji.
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